Slate Asset Management Appoints Bozena Jankowska as Managing Director and Global Head of ESG
23.11.2021 11:00:00 EET | Business Wire | Press release
Slate Asset Management ("Slate" or “the firm”), a global alternative investment platform focused on real estate, today announced that it has appointed Bozena Jankowska as Managing Director and Global Head of Environmental, Social and Governance (“ESG”), based in Slate’s London office.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005469/en/
Bozena Jankowska, Managing Director and Global Head of ESG at Slate Asset Management (Photo: Business Wire)
Jankowska has nearly two decades of experience at the intersection of finance and corporate responsibility. She will lead the development of best-in-class ESG practices and policies aimed at safeguarding the long-term performance of Slate’s global investments. Additionally, Jankowska will oversee and advance Slate’s corporate social responsibility strategy and the integration of ESG into Slate’s investment and asset management processes, as well as stakeholder communications and reporting. Her focus over the next year will be to complete an ESG assessment of Slate’s assets under management, with an initial focus on Europe, before subsequently expanding to the entirety of Slate’s global platform.
“We are very pleased to welcome Bozena to our team,” said Brady Welch, Founding Partner at Slate. “From the outset, Bozena’s commitment to innovation and her entrepreneurial spirit set her apart from other candidates. She led the drive for sustainability in the finance industry well before it became mainstream, and her deep-rooted technical knowledge of complex global sustainability topics will be extremely valuable as we continue driving our ESG strategy forward.”
Blair Welch, Founding Partner at Slate Asset Management, added: “We understand that having sound ESG practices underpinning our approach to investment and asset management benefits our tenants, our communities and our investors. Bozena’s appointment displays our deep commitment to embedding ESG principles across our business.”
Jankowska was Global Co-Head of ESG at Allianz Global Investors (“AGI”), responsible for ESG integration across the firm’s investment portfolio. During her 15-year tenure at AGI, she pioneered a number of innovative ESG strategies and processes, establishing a global ESG team and growing AGI’s total sustainable investment assets under management from €70 million to over €30 billion. She also designed, managed and marketed the Allianz Global Investors clean technology fund – Global Ecotrends – which grew from $10 million in seed funding to $1 billion in assets under management, becoming a global franchise for the firm.
After leaving AGI, Jankowska founded a successful women’s sustainable fashion label, overseeing the brand’s business strategy and creative direction, including sustainable materials research and sourcing, supply chain management, and successful partnerships with non-governmental organizations focused on environmental sustainability.
“I am excited to join an organization that clearly understands how best-in-class ESG practices can play a critical role in long-term value creation,” said Jankowska. “I look forward to working with the team at Slate to continue raising the bar on the firm’s ESG performance and identifying new and innovative ways to add further rigor to our ESG approach.”
Jankowska holds a Bachelor of Science in Environmental Science from the University of Sussex. She completed her Master of Science in Environment Technology with distinction at Imperial College.
Jankowska joined Slate on November 22.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform focused on real estate. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005469/en/
Contact information
Slate Asset Management
Karolina Kmiecik
Karolina@slateam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom